Disease Areas

Atrial fibrillation

"PAUSE" protocol safe for AF patients on DOAC therapy who need surgery (7/8/2019) ›Catheter ablation improves outcomes in atrial fibrillation with heart failure (1/8/2019) ›Former US pro football players may face increased risk of Afib (25/7/2019) ›NOACs best for Afib in early kidney disease, but jury out in advanced CKD (15/7/2019) ›Heparin bridging could worsen outcomes after stroke (9/7/2019) ›New method of interpreting cardiac telemetry accurately spots AF in stroke patients (4/7/2019) ›DOACs better choice for Asian patients with AF and liver disease (4/7/2019) ›Avoid VKA plus DAPT in AF patients undergoing PCI: meta-analysis (28/6/2019) ›Atrial fibrillation tied to increased risk of dementia (27/6/2019) ›Beta-blockers may attenuate triggering of atrial fibrillation by anger, stress (25/6/2019) ›Direct oral anticoagulants, warfarin appear equally safe in morbidly obese patients (13/6/2019) ›Long-standing AF tied to outcomes of left-atrial-appendage occlusion (6/6/2019) ›New-onset atrial fibrillation common after aortic-valve replacement (4/6/2019) ›Worse outcomes seen in AF patients with ischemic cardiomyopathy (23/5/2019) ›Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin (18/3/2019) ›Smartwatch can detect atrial fibrillation with high degree of accuracy (18/3/2019) ›Lower rates stroke/SE with DOACs in frail non-valvular AF patients (18/3/2019) ›Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry (18/3/2019) ›Substantial impact of temporary interruptions of warfarin versus DOAC (18/3/2019) ›2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (18/3/2019) ›

Breast cancer

Dense breast notification laws not leading to more screening ultrasounds (8/8/2019) ›Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer (22/7/2019) ›ImPassion130 brings breast cancer into the immunotherapy era (22/7/2019) ›Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer (22/7/2019) ›Strategy helps identify candidates for supplemental breast imaging (2/7/2019) ›Digital breast tomosynthesis now favored by more than 40% of hospital referral regions (27/6/2019) ›Niraparib-pembrolizumab combo may have benefit in ovarian, breast cancers (20/6/2019) ›Cardioprotective drugs can help avoid chemo disruption in some breast cancer patients (5/6/2019) ›Ribociclib plus hormone therapy prolongs survival of younger patients with advanced breast cancer (3/6/2019) ›Novartis' breast cancer treatment wins FDA approval (24/5/2019) ›Nipple-sparing mastectomy safe for more women with breast cancer (9/5/2019) ›Bioimpedance spectroscopy helps prevent breast cancer-related lymphedema progression (8/5/2019) ›Low-dose tamoxifen prevents recurrence of in situ breast cancer (3/5/2019) ›HER2 testing inaccessible for many women with breast cancer (2/5/2019) ›Promising strategy identifies triple-negative breast cancers that might respond to tamoxifen (23/4/2019) ›Surgery after systemic therapy tied to improved outcome of HER2+ advanced breast cancer (5/4/2019) ›Fulvestrant-anastrozole combo improves survival in metastatic breast cancer (27/3/2019) ›Fewer benign biopsies with digital breast tomosynthesis (26/3/2019) ›St. Gallen Consensus - DCIS: de-escalation of (adjuvant) therapy (23/3/2019) ›Letter from the editor (23/3/2019) ›History of the consensus meeting (23/3/2019) ›St. Gallen Consensus - Primary surgery: margins (23/3/2019) ›St. Gallen Consensus - Skin and nipple sparing surgery: still a matter of debate (23/3/2019) ›St. Gallen Consensus - Surgery of the axilla: indications decrease (23/3/2019) ›New prognostic biomarkers for survival breast cancer (23/3/2019) ›Discordance of biomarkers in multifocal and lymph node positive breast cancer (23/3/2019) ›Adjuvant and neoadjuvant therapy: principles and practical considerations (23/3/2019) ›What is the clinical benefit of treatment of patients with early breast cancer? (23/3/2019) ›Extrapolating data from clinical trials as we treat patients in real life (23/3/2019) ›St. Gallen Consensus - Life style (23/3/2019) ›St. Gallen Consensus - Pregnancy after breast cancer (23/3/2019) ›St. Gallen Consensus - Germ-line mutations (23/3/2019) ›St. Gallen Consensus - Bisphosphonates and denosumab (23/3/2019) ›St. Gallen Consensus - Adjuvant therapy in triple-negative breast cancer (23/3/2019) ›St. Gallen Consensus - Adjuvant Her2-targeted therapy (23/3/2019) ›St. Gallen Consensus - Endocrine therapy in postmenopausal patients: a graded approach (23/3/2019) ›St. Gallen Consensus - Endocrine therapy in premenopausal patients (23/3/2019) ›St. Gallen Consensus - Adjuvant chemotherapy after neoadjuvant chemotherapy? Going beyond EMA/FDA (23/3/2019) ›St. Gallen Consensus - Neoadjuvant therapy and residual disease (23/3/2019) ›St. Gallen Consensus - Gene expression signatures (23/3/2019) ›Selection of patients for neoadjuvant chemotherapy treatment based on oncotype recurrence score in luminal breast cancer (23/3/2019) ›Screening ultrasonography does not improve breast-cancer detection (21/3/2019) ›Breast cancer risk tied to DDT varies by exposure timing (14/3/2019) ›Heart-failure risk increased after adjuvant trastuzumab for breast cancer (28/2/2019) ›Long-lasting menopause symptoms may be tied to slightly higher breast cancer risk (17/1/2019) ›Task force adds aromatase inhibitors to advice on breast cancer chemoprevention in high-risk women (15/1/2019) ›

Cancer

Nivolumab therapy tied to better long-term survival in some cancer patients (2/8/2019) ›Lymphedema after axillary node dissection linked with obesity, longer neoadjuvant chemo (25/7/2019) ›IL-6 and C-reactive protein as potential biomarkers for checkpoint inhibition (23/7/2019) ›First-in-human study shows IL1RAP-targeting drug safe in solid tumours (23/7/2019) ›More people developing colorectal cancer before age 50 (22/7/2019) ›Letter from the Editors (22/7/2019) ›Olaratumab trial in soft tissue sarcoma fails to meet overall survival endpoint (22/7/2019) ›Deep-learning tool can help individualize radiotherapy doses based on imaging (11/7/2019) ›European urologists release position paper on immune checkpoint inhibitor toxicities (2/7/2019) ›Checkpoint inhibitors may be retried after immune adverse event, with close monitoring (12/6/2019) ›Only 13% of patients eligible for checkpoint inhibitors respond to them (13/5/2019) ›Numerous new anticancer drugs not proven superior to standard of care (9/5/2019) ›Molecular profiling identifies potential treatment targets in many hard-to-treat pediatric cancers (7/5/2019) ›High-dose, single-fraction SBRT likely effective for non-spine bone metastases (2/5/2019) ›Adverse events common with PD-1 and PD-L1 inhibitors (1/5/2019) ›Many young cancer patients regret initial treatment decisions (23/4/2019) ›Study of AYA-cancer survivors can guide surveillance for new primary neoplasms (28/2/2019) ›Tisotumab vedotin shows some promise in early trial of solid tumors (19/2/2019) ›Hyperthermic intraperitoneal chemo relatively safe for treating metastases (7/2/2019) ›Hypothermic intraperitoneal chemo relatively safe for treating metastases (31/1/2019) ›Tumor markers limit imaging need in germ-cell tumor surveillance (16/1/2019) ›Life expectancy predicts benefit of immune-checkpoint inhibitors (15/1/2019) ›Brain metastases, lung cancer and interstitial lung disease (19/9/2018) ›ALK inhibition, guidelines, liquid biopsies, and immunotherapy (19/9/2018) ›EGFR-targeted treatments (19/9/2018) ›Cancer risk in IBD associated with age and recent immunomodulator use (19/9/2018) ›Malignancies occur infrequently with tofacitinib (17/2/2018) ›Significantly increased risk of CRC and/or HGD after appendectomy in UC (17/2/2018) ›SLC12A2 potential marker of dysplasia associated to inflammation in UC (17/2/2018) ›Shallow whole-genome sequencing predicts future cancer risk of LGD in UC (17/2/2018) ›Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD (17/2/2018) ›

Crohn's disease

UC disease course similar for smokers, non-smokers (16/8/2019) ›Mesenchymal-stromal-cell therapy effective long-term for Crohn's disease perianal fistulas (26/7/2019) ›Vedolizumab brings endoscopic remission in some patients with Crohn's disease (22/7/2019) ›Nutritional approach brings sustained remission in Crohn's disease (5/7/2019) ›Proactive drug monitoring improves outcomes in kids with Crohn’s (25/6/2019) ›Early endoscopic remission linked to altered course of Crohn's disease (29/5/2019) ›Machine-learning models help predict remission in Crohn's (23/5/2019) ›Ustekinumab as maintenance therapy and with shortened interval (14/5/2019) ›Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease (14/5/2019) ›Relapse after withdrawal of thiopurines (14/5/2019) ›Early remission of Crohn’s disease prevents progression (14/5/2019) ›Proactive adalimumab trough measurements increase corticosteroid-free clinical remission (14/5/2019) ›Efficacy and safety of biosimilars (14/5/2019) ›The costs and benefits of biologicals (14/5/2019) ›Infliximab retreatment in luminal Crohn’s disease (14/5/2019) ›Pathogenesis (14/5/2019) ›Immune cells and microbes: a happy marriage? (14/5/2019) ›Moving towards new therapeutic options (14/5/2019) ›ZNF133 associated with infliximab response (14/5/2019) ›Network analysis of GWAS (14/5/2019) ›Gene expression signature predicts non-response (14/5/2019) ›Ustekinumab beneficial in refractory Crohn's disease in real world (30/4/2019) ›MR enterography best identifies fibrotic vs inflammatory strictures in Crohn's disease (23/4/2019) ›Infliximab biosimilar CT-P13 noninferior in active Crohn's disease (9/4/2019) ›T cell clonal expansion linked to postop recurrence of Crohn's in smokers (11/3/2019) ›New risk score helps predict intra-abdominal abscess in Crohn's disease (5/3/2019) ›Treg cells show promise as immunotherapy for Crohn's disease (13/2/2019) ›Adding vedolizumab to steroids may boost response, remission in Crohn's disease (30/1/2019) ›Postpartum substance abuse, mood disorders more common with IBD (25/1/2019) ›Early and significant effects with upadacitinib induction treatment (17/2/2018) ›SHP647 is efficacious and well-tolerated in CD (17/2/2018) ›Comparative effectiveness of vedolizumab and ustekinumab in CD (17/2/2018) ›Vedolizumab induces endoscopic remission and healing in refractory CD (17/2/2018) ›

Inflammatory bowel disease

Haematopoietic stem cells can sense tissue damage in the gut (21/8/2019) ›Patient-clinician toolkit can ease transition from pediatric to adult IBD care (7/8/2019) ›Less positive emotional-recognition bias linked to depression in IBD (12/7/2019) ›Anti-TNF alpha agents tied to increased IBD risk (11/7/2019) ›Overall diet quality in many with IBS is poor (23/5/2019) ›Hypoalbuminemia linked to worse outcomes after IBD surgery (15/5/2019) ›Glycans as novel immunomodulators in inflammatory bowel disease (14/5/2019) ›Topical review (14/5/2019) ›Complementary and alternative medicine associated with chronic fatigue and lower QoL (14/5/2019) ›Microbial composition and psychological wellbeing (14/5/2019) ›The costs and benefits of biologicals (14/5/2019) ›Novel host-microbiome interactions in inflammatory bowel disease (14/5/2019) ›Safety of thiopurine + allopurinol vs thiopurine monotherapy (14/5/2019) ›IBD risk of treatment with IL-17 antagonists (14/5/2019) ›Novel test predicts IBD course at diagnosis (13/5/2019) ›Breath analysis shows promise in distinguishing IBD types (9/5/2019) ›Immunosuppressants found safe for IBD patients with cancer history (30/4/2019) ›Sleeve gastrectomy may be safer than gastric bypass for IBD patients (28/2/2019) ›Azathioprine ups pancreatitis risk in pediatric IBD (31/1/2019) ›Postpartum substance abuse, mood disorders more common with IBD (25/1/2019) ›Advanced endoscopic techniques improve IBD assessment (8/1/2019) ›Cancer risk in IBD associated with age and recent immunomodulator use (19/9/2018) ›Clinical effect of vedolizumab on articular manifestations spondyloarthritis associated with IBD (16/6/2018) ›Quiescent disease, characteristics and biomarker correlations (20/2/2018) ›Significant reduction of emergency stoma surgeries for CD (17/2/2018) ›Genetic predisposition for gut barrier dysfunction (17/2/2018) ›ILC1 distribution predicts response to ustekinumab (17/2/2018) ›Integration of “omics” and potential for clinical practice (17/2/2018) ›Targeting early disease: lessons from rheumatoid arthritis (17/2/2018) ›Higher rates of remission and healing with vedolizumab vs. TNF antagonist (17/2/2018) ›Overall manageable safety profile of tofacitinib in long-term use (17/2/2018) ›Vedolizumab in anti-TNF-naïve IBD patients and safety profile (17/2/2018) ›Higher colectomy rate with infliximab vs. conventional therapies in more severe UC (17/2/2018) ›Central role of IL-23 in molecular resistance to anti-TNF therapy (17/2/2018) ›Shallow whole-genome sequencing predicts future cancer risk of LGD in UC (17/2/2018) ›Long-term safety profile of adalimumab (17/2/2018) ›SLC12A2 potential marker of dysplasia associated to inflammation in UC (17/2/2018) ›Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD (17/2/2018) ›Enhanced post-operative recovery pathways for IBD patients (17/2/2018) ›Significantly increased risk of CRC and/or HGD after appendectomy in UC (17/2/2018) ›Malignancies occur infrequently with tofacitinib (17/2/2018) ›Combining new drugs with different mechanisms (17/2/2018) ›Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines (17/2/2018) ›

Leukemia

Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL (21/8/2019) ›Overcoming the “Don’t Eat Me” signal in AML and MDS (21/8/2019) ›Initial data on AMV564 in patients with relapsed/refractory AML (21/8/2019) ›Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia (21/8/2019) ›Transformation of foetal haematopoietic stem and progenitor cells in the background of trisomy 21 (21/8/2019) ›ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL (21/8/2019) ›Residual disease in AML patients prior to stem cell transplant increases relapse risk (21/8/2019) ›Venetoclax-obinutuzumab combination elicits high response rates in CLL (21/8/2019) ›CAR-T cell therapy in ALL as breakthrough advance (21/8/2019) ›Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL (21/8/2019) ›Guadecitabine vs treatment of choice in AML (21/8/2019) ›Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML (21/8/2019) ›Ibrutinib-based therapy better than conventional treatment for CLL (31/7/2019) ›Evidence of residual disease in AML patients prior to stem cell transplant increases post-transplant relapse risk (13/6/2019) ›Venetoclax-obinutuzumab combination elicits high response rates in CLL (13/6/2019) ›Acalabrutinib improves progression-free survival in relapsed or refractory CLL in the ASCEND study (13/6/2019) ›Overcoming the “Don’t Eat Me” signal in AML and MDS (13/6/2019) ›Venetoclax combination better than chlorambucil in CLL patients with coexisting conditions (4/6/2019) ›Drug combination may be effective against chronic lymphocytic leukemia (29/5/2019) ›FDA okays Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia (16/5/2019) ›Leukaemia therapy nilotinib effective in Parkinson’s disease (7/5/2019) ›Gilteritinib improves survival in relapsed/refractory acute myeloid leukemia (2/4/2019) ›

Lung cancer

Lurbinectedin shows promise as second-line therapy for SCLC (23/7/2019) ›Overcoming the challenges of immunotherapy in non–small cell lung cancer (23/7/2019) ›Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC (23/7/2019) ›Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC (23/7/2019) ›Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC (23/7/2019) ›Early results from TAK-788 in NSCLC with EGFR exon 20 insertions (23/7/2019) ›Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC (23/7/2019) ›Lung-cancer-screening eligibility should be expanded (18/7/2019) ›WHO keeps key lung cancer drugs off its essential medicines list (9/7/2019) ›Antioxidants enhance lung cancer metastasis by stabilizing BACH1 (8/7/2019) ›High prevalence of PD-L1 expression in non-small-cell lung cancer (5/7/2019) ›Lung-cancer screening may be warranted in bladder-cancer patients (2/7/2019) ›Other I-O combinations (1/7/2019) ›Experiences from Germany (1/7/2019) ›How can societies help to implement personalised treatment? (1/7/2019) ›Experiences from France (1/7/2019) ›Post-discontinuation immunotherapy in PACIFIC (1/7/2019) ›Post-study immunotherapy in MYSTIC (1/7/2019) ›Molecular characteristics of SCLC (1/7/2019) ›Immunotherapy in SCLC: trial data (1/7/2019) ›Systemic therapy of brain metastases (1/7/2019) ›Incidence and local treatment (1/7/2019) ›I-O monotherapy (1/7/2019) ›Genomic and immune profiling (1/7/2019) ›Electromagnetic navigation bronchoscopy (1/7/2019) ›Treatment options in early NSCLC (1/7/2019) ›Tumour, node, and metastasis (TNM) staging system (1/7/2019) ›Combo I-O plus chemotherapy (1/7/2019) ›Predictive diagnostics for I-O (1/7/2019) ›Brain irradiation as treatment option (1/7/2019) ›Lung cancer radiotherapy tied to higher cardiac mortality (18/6/2019) ›Broadening eligibility for lung cancer trials could have huge impact (5/6/2019) ›Pembrolizumab quadruples survival in selected advanced non-small cell lung cancer patients (3/6/2019) ›Atezolizumab added to chemo ups survival in lung cancer (31/5/2019) ›Longer lung-cancer-screening intervals may sometimes be OK (27/5/2019) ›Vein-first ligation in lung-cancer surgery may increase survival (14/5/2019) ›New technique for minimally invasive lung cancer surgery promising (10/5/2019) ›Higher radiation doses tied to increased longevity in node-negative lung cancer (30/4/2019) ›Deep-learning model may help predict NSCLC outcomes, survival (30/4/2019) ›Lung-cancer survival worse in patients with pulmonary fibrosis (25/4/2019) ›Post-study immunotherapy confounds primary survival outcome (11/4/2019) ›Immunotherapy in elderly: diverse findings across the globe (11/4/2019) ›Survival benefit persists despite post-discontinuation therapy (11/4/2019) ›Electromagnetic navigation: an instant hit? (11/4/2019) ›Comprehensive profiling in localised stage lung cancer (11/4/2019) ›Next-generation sequencing assay detects genetic variants driving cancer, resistance in NSCLC (2/4/2019) ›Pembrolizumab may help some with advanced non-small-cell lung cancer (2/4/2019) ›Cranial irradiation doesn't boost survival in locally advanced lung cancer (26/3/2019) ›Lung-cancer screens effective in asbestos-exposed smokers (14/3/2019) ›Liquid biopsy on par with tissue testing in advanced lung cancer (5/3/2019) ›Stereotactic ablative radiotherapy tops for inoperable early non-small-cell lung cancer (21/2/2019) ›It's never too late to quit smoking before lung surgery (16/1/2019) ›Lung cancer screening complications may be higher than expected (14/1/2019) ›Interview with IASCL President (26/9/2018) ›Small-cell lung cancer circulating tumour cell derived explants (26/9/2018) ›Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Prognostic value of distant organ-specific metastases in newly diagnosed lung neuroendocrine tumours (26/9/2018) ›Spread through air spaces is prognostic in lung neuroendocrine tumours (26/9/2018) ›Entrectinib treatment in patients with ROS1+ NSCLC (26/9/2018) ›Angiogenic and stromal biomarkers in malignant mesothelioma (26/9/2018) ›Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer (26/9/2018) ›Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (26/9/2018) ›Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC (26/9/2018) ›Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer (26/9/2018) ›Next generation immunotherapy in non-small-cell lung cancer (26/9/2018) ›Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer (26/9/2018) ›Combination therapies: Where are we in 2018? (26/9/2018) ›Unmet needs in surgical management of malignant pleural mesothelioma (26/9/2018) ›PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib (26/9/2018) ›Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative (26/9/2018) ›Benefits of chest CT screening (26/9/2018) ›New standard of care in extensive-stage small-cell lung cancer (26/9/2018) ›Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer (26/9/2018) ›Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer (26/9/2018) ›No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype (26/9/2018) ›

Prostate cancer

Better detection of clinically significant prostate cancer with MRI plus targeted biopsy (15/8/2019) ›Worse short-term mortality among men with prostate cancer and cardiovascular disease (15/8/2019) ›Waterjet ablation effective for treating benign prostatic obstruction (9/8/2019) ›Obesity tied to worse perioperative outcomes of radical prostatectomy (8/8/2019) ›Elective node radiation appears more effective for nodal-recurrent prostate cancer (5/8/2019) ›MRI bests systematic biopsies for diagnosing prostate cancer (31/7/2019) ›Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer (23/7/2019) ›Enzalutamide offers survival advantage over other NSAAs in mHSPC (23/7/2019) ›Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma (23/7/2019) ›Fast MRI protocol accurately identifies prostate cancer at lower cost (19/7/2019) ›Decision aids for prostate-cancer screening of limited value (28/6/2019) ›Prostate cancer: Early enzalutamide substantially improves time to progression and overall survival when added to standard mHSPC therapy (testosterone suppression ± docetaxel) (3/6/2019) ›Apalutamide boosts progression-free survival by 52% in some prostate cancer patients (31/5/2019) ›Sipuleucel-T could be more widely used for advanced prostate cancer (25/4/2019) ›Lower risk of new primary cancer after carbon-ion radiotherapy of localized prostate cancer (12/4/2019) ›Prostate cancer: what to expect the next 12 months (19/3/2019) ›Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer. (19/3/2019) ›Heart disease boosts risk for early death with abiraterone therapy for prostate cancer (6/3/2019) ›Hypofractionated radiotherapy appropriate for low-risk prostate cancer (22/2/2019) ›Expanding genetic testing for prostate cancer could improve patient management (15/2/2019) ›Stereotactic body radiotherapy shows long-term safety in prostate cancer (14/2/2019) ›Novel radiation therapy promising for metastatic castration-resistant prostate cancer (14/2/2019) ›Focal cryotherapy shows encouraging prostate cancer control (31/1/2019) ›

Psoriasis

Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies (18/6/2019) ›Reduction in coronary artery disease in psoriasis patients treated with biologic therapies (18/6/2019) ›Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis? (18/6/2019) ›Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies (18/6/2019) ›ABP501 Biosimilar for adalimumab: What you need to know (18/6/2019) ›Switching infliximab biosimilars safe in treating chronic plaque psoriasis (18/6/2019) ›Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis (18/6/2019) ›Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease in patients with moderate-to-severe plaque psoriasis (18/6/2019) ›Treatment goals in psoriasis (18/6/2019) ›Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (18/6/2019) ›Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity (18/6/2019) ›Favourable safety profile of long-term use of ixekizumab (18/6/2019) ›Advances in target-oriented therapy: psoriatic arthritis (18/6/2019) ›Atopic dermatitis and psoriasis: on a spectrum? (18/6/2019) ›Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis (18/6/2019) ›Small molecules, apremilast, and TYK2 (18/6/2019) ›Novel selective IL-23 blocker highly effective over 2 years (10/6/2019) ›The role of the gut-skin axis in dermatology, specifically psoriasis (10/6/2019) ›Etanercept biosimilar shows preliminary efficacy in psoriasis and psoriatic arthritis (10/6/2019) ›Infliximab associated with a 3-fold risk of serious infections (10/6/2019) ›Plaque psoriasis – Efficacy of guselkumab (25/4/2019) ›Serlopitant reduces pruritus associated with psoriasis (25/4/2019) ›Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis (25/4/2019) ›Secukinumab maintains improvements in psoriasis through 5 years of treatment (25/4/2019) ›Psoriasis and Biologics: The Beat Goes On (25/4/2019) ›Oral therapeutics, supersaturation and excimer laser (20/2/2018) ›Living in the golden age of psoriasis and atopic dermatitis therapies (20/2/2018) ›Biologics in psoriasis and new selective IL-23 blockers (20/2/2018) ›Psoriasis management online? (20/2/2018) ›Intralesional cryosurgery and itching in psoriasis (20/2/2018) ›Improvement in impact of genital psoriasis on sexual activity with use of ixekizumab (20/2/2018) ›Better gastrointestinal tolerability with biologics than the conventional therapy (20/2/2018) ›Psoriasis: Selective IL-23 blocker, analysis of VOYAGE-2, dual IL-17 inhibitor and ustekinumab (20/2/2018) ›

Subscribe for free ›

Stay up-to-date with Medicom. Subscribe to the Medicom Conference Reports and newsletter.

About us ›

Medicom provides the highest quality medical information and tools to international medical professionals.